Biotechnology US drugmaker AbbVie over the weekend released new 52-week data from an open-label, single-arm study demonstrating improved plaque psoriasis signs and symptoms among a difficult-to-treat patient population who received Skyrizi (risankizumab), an interleukin (IL)-23 inhibitor, during the 2023 American Academy of Dermatology (AAD) Annual Meeting taking place in New Orleans, Louisiana. 20 March 2023